Cerulean Pharma Inc. (CERU) Trading 9.6% Higher
Cerulean Pharma Inc. (NASDAQ:CERU) traded up 9.6% during trading on Friday . The company traded as high as $2.52 and last traded at $2.29, with a volume of 385,410 shares trading hands. The stock had previously closed at $2.09.
A number of equities research analysts recently commented on the stock. Canaccord Genuity reissued a “buy” rating on shares of Cerulean Pharma in a research note on Tuesday, May 3rd. Janney Montgomery Scott assumed coverage on shares of Cerulean Pharma in a research note on Wednesday, June 1st. They issued a “buy” rating on the stock. Leerink Swann reissued a “buy” rating on shares of Cerulean Pharma in a research note on Sunday, June 26th. Finally, Wedbush reissued an “outperform” rating and issued a $9.00 price objective on shares of Cerulean Pharma in a research note on Tuesday, April 19th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Cerulean Pharma has a consensus rating of “Buy” and a consensus price target of $9.28.
The firm has a 50-day moving average of $2.22 and a 200 day moving average of $2.51. The company’s market cap is $62.39 million.
Cerulean Pharma (NASDAQ:CERU) last issued its quarterly earnings data on Monday, May 2nd. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.06. Equities research analysts anticipate that Cerulean Pharma Inc. will post ($1.80) earnings per share for the current year.
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.